Compass Pathways/CMPS

$8.48

1.44%
-
1D1W1MYTD1YMAX

About Compass Pathways

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Ticker

CMPS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kabir Nath

Employees

186

Headquarters

Altrincham, United Kingdom

Compass Pathways Metrics

BasicAdvanced
$572.71M
Market cap
-
P/E ratio
-$2.39
EPS
2.37
Beta
-
Dividend rate
$572.71M
2.37409
$12.75
$5.01
714.51K
13.329
12.739
12.739
-50.06%
-58.21%
-54.08%
2.299
2.537
-10.61%

What the Analysts think about Compass Pathways

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
386.44% upside
High $120.00
Low $22.00
$8.48
Current price
$41.25
Average price target

Compass Pathways Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-32.5M
-2.4%
Profit margin
0%
-

Compass Pathways Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 60.61%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.57
-$0.62
-$0.67
-$0.53
-
Expected
-$0.68
-$0.69
-$0.43
-$0.33
-$0.49
Surprise
-16.77%
-10.66%
54.28%
60.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Compass Pathways stock?

Compass Pathways (CMPS) has a market cap of $572.71M as of April 24, 2024.

What is the P/E ratio for Compass Pathways stock?

The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of April 24, 2024.

Does Compass Pathways stock pay dividends?

No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Compass Pathways dividend payment date?

Compass Pathways (CMPS) stock does not pay dividends to its shareholders.

What is the beta indicator for Compass Pathways?

Compass Pathways (CMPS) has a beta rating of 2.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Compass Pathways stock price target?

The target price for Compass Pathways (CMPS) stock is $41.25, which is 400% above the current price of $8.25. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Compass Pathways stock

Buy or sell Compass Pathways stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing